Hyku
About:
Hyku is a biotech company that develops precise covalent targeting of disease-causing proteins.
Website: https://www.hykubiosciences.com
Top Investors: RA Capital Management, KB Investment, Novartis Venture Fund, Droia Ventures, The Mark Foundation for Cancer Research
Description:
Hyku is a biotech company that develops precise covalent targeting of disease-causing proteins. The Hyku platform identifies molecules that covalently bind non-cysteine amino acids to aid in the creation of innovative medicines that can address present issues with a variety of disease targets, such as selectivity, druggability, and resistance.
$56M
Lexington, Massachusetts, United States
2021-01-01
Milind Deshpande
11-50
2023-09-19
Private
© 2025 bioDAO.ai